{
  "company": {
    "ticker": "MRNA",
    "name": "Moderna Inc.",
    "category": [
      "Biotech"
    ],
    "sector": "Healthcare",
    "subCategory": "Biotech",
    "cik": "0001682852"
  },
  "reports": [
    {
      "filing": {
        "accessionNumber": "0001682852-25-000075",
        "filingDate": "2025-11-06",
        "reportDate": "2025-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/1682852/000168285225000075/mrna-20250930.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "weak",
        "headcountTrend": "stable",
        "revenue": 973,
        "netIncome": -200,
        "operatingCashFlow": null,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 320,
        "marketShareMention": null,
        "customerConcentration": null,
        "geographicBreakdown": {
          "United_States": 80.4,
          "Europe": 1.6,
          "Rest_of_World": 18
        },
        "capexAmount": 153,
        "capexGrowth": null,
        "partnerships": [
          "Australian Government mRNA Manufacturing Facility",
          "UK Government mRNA Manufacturing Facility",
          "Canadian Government mRNA Manufacturing Facility",
          "Merck collaboration on cancer vaccines"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "defensive",
        "overallSentiment": "bearish",
        "summary": "Moderna experienced a challenging quarter with significant net loss and reduced product sales, driven by declining COVID vaccine demand. The company continues to invest in diversifying its pipeline across vaccines and therapeutics while managing cost structures.",
        "keyQuotes": [
          "We continue to make progress on advancing mRNA-4157 in the clinic.",
          "Our ongoing Phase 3 safety and efficacy study of our trivalent vaccine candidate against norovirus (mRNA-1403) has not accrued sufficient cases.",
          "We will discontinue our congenital CMV clinical development program."
        ],
        "marketData": {
          "priceOnEarningsDate": 25.829999923706055,
          "priceAfter7Days": 27.34000015258789,
          "priceChangePercent": 5.845916505388758,
          "managementToneScore": 5,
          "earningsBeatScore": 50,
          "priceActionScore": 70,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 52,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q3 2025",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2025,
        "fiscalQuarter": 3,
        "fiscalYear": 2025,
        "quarter": "Q3 2025",
        "reportDate": "2025-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0001682852-25-000044",
        "filingDate": "2025-08-01",
        "reportDate": "2025-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/1682852/000168285225000044/mrna-20250630.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "weak",
        "headcountTrend": "reducing",
        "revenue": 142,
        "netIncome": -825,
        "operatingCashFlow": -1956,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 283,
        "marketShareMention": null,
        "customerConcentration": null,
        "geographicBreakdown": {
          "US": 88,
          "RestOfWorld": 26
        },
        "capexAmount": 120,
        "capexGrowth": null,
        "partnerships": [
          "Merck collaboration on personalized cancer vaccines",
          "Blackstone funding for influenza vaccine development"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Terminated pandemic influenza vaccine development award from HHS"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": false,
        "managementTone": "defensive",
        "overallSentiment": "bearish",
        "summary": "Moderna continues to face challenges with declining COVID vaccine sales and ongoing losses. The company is expanding its product portfolio with new RSV and next-generation COVID vaccines while maintaining a diverse clinical pipeline across multiple therapeutic areas.",
        "keyQuotes": [
          "We are developing medicines across four franchises: respiratory virus vaccines, latent and other virus vaccines, oncology therapeutics and rare disease therapeutics.",
          "We anticipate seasonal fluctuations in demand for our COVID and RSV vaccines, with higher sales expected during the fall and winter seasons."
        ],
        "marketData": {
          "priceOnEarningsDate": 27.59000015258789,
          "priceAfter7Days": 29.899999618530273,
          "priceChangePercent": 8.372596785671671,
          "managementToneScore": 5,
          "earningsBeatScore": 50,
          "priceActionScore": 80,
          "guidanceAccuracyScoreWeighted": 25,
          "compositeSentimentScore": 50,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q2 2025",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2025,
        "fiscalQuarter": 2,
        "fiscalYear": 2025,
        "quarter": "Q2 2025",
        "reportDate": "2025-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0001682852-25-000034",
        "filingDate": "2025-05-01",
        "reportDate": "2025-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/1682852/000168285225000034/mrna-20250331.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "weak",
        "headcountTrend": "reducing",
        "revenue": 108,
        "netIncome": -971,
        "operatingCashFlow": -1037,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 154,
        "marketShareMention": null,
        "customerConcentration": null,
        "geographicBreakdown": {
          "United_States": 28.7,
          "Rest_of_World": 71.3
        },
        "capexAmount": 117,
        "capexGrowth": null,
        "partnerships": [
          "Merck (Individualized Neoantigen Therapy)",
          "BARDA (vaccine development)",
          "Blackstone Life Sciences (influenza vaccine funding)"
        ],
        "supplyChainStatus": "tight",
        "regulatoryHeadwinds": [
          "FDA review timelines",
          "Seasonal vaccine market complexity"
        ],
        "aiInvestmentMentioned": true,
        "priorGuidanceHit": false,
        "managementTone": "defensive",
        "overallSentiment": "bearish",
        "summary": "Moderna experienced a significant decline in COVID vaccine sales and continues to manage costs while advancing its pipeline. The company is strategically prioritizing late-stage programs and managing expenses, but faces challenges in vaccine demand and market competition.",
        "keyQuotes": [
          "As COVID has transitioned to a seasonal respiratory vaccine, we anticipate a decline in net product sales for the full year 2025",
          "We are maintaining investments in late-stage programs, including our INT, norovirus, CMV, and combination vaccine programs",
          "We continue to advance our pipeline, with a focused approach to execution"
        ],
        "marketData": {
          "priceOnEarningsDate": 28.350000381469727,
          "priceAfter7Days": 25.639999389648438,
          "priceChangePercent": -9.559086262279608,
          "managementToneScore": 5,
          "earningsBeatScore": 50,
          "priceActionScore": 15,
          "guidanceAccuracyScoreWeighted": 25,
          "compositeSentimentScore": 30,
          "compositeSentiment": "bearish"
        }
      },
      "quarter": "Q1 2025",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2025,
        "fiscalQuarter": 1,
        "fiscalYear": 2025,
        "quarter": "Q1 2025",
        "reportDate": "2025-03-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0001682852-25-000022",
        "filingDate": "2025-02-21",
        "reportDate": "2024-12-31",
        "form": "10-K",
        "url": "https://www.sec.gov/Archives/edgar/data/1682852/000168285225000022/mrna-20241231.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "weak",
        "headcountTrend": "stable",
        "revenue": 872,
        "netIncome": null,
        "operatingCashFlow": null,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": "Experienced decline in COVID vaccine market share",
        "customerConcentration": null,
        "geographicBreakdown": null,
        "capexAmount": null,
        "capexGrowth": null,
        "partnerships": [
          "Vertex (Cystic Fibrosis program)",
          "Merck (Individualized Neoantigen Therapies)",
          "Institute for Life Changing Medicines",
          "DARPA",
          "BARDA",
          "Vertex",
          "Merck",
          "AstraZeneca",
          "Blackstone Life Sciences",
          "Immatics",
          "UK Health Security Agency",
          "FFF Enterprises",
          "Taiwan Food and Drug Administration",
          "European Commission",
          "US Government",
          "Takeda Pharmaceutical Company",
          "Ministry of Health Labor and Welfare of Japan",
          "National Institutes of Allergy and Infectious Diseases"
        ],
        "supplyChainStatus": "tight",
        "regulatoryHeadwinds": [
          "FDA scrutiny of mRNA vaccine side effects",
          "Potential gene therapy classification risks",
          "Post-marketing study requirements"
        ],
        "aiInvestmentMentioned": true,
        "priorGuidanceHit": null,
        "managementTone": "defensive",
        "overallSentiment": "neutral",
        "summary": "Moderna faces market challenges with declining COVID vaccine sales and limited RSV vaccine market penetration. The company is pivoting to diversify its pipeline, investing in AI technologies and exploring multiple therapeutic areas while managing regulatory and manufacturing complexities.",
        "keyQuotes": [
          "We continue to build our differentiated commercial model",
          "Our digital and AI infrastructure allows our scientists to design novel mRNA constructs",
          "We are encouraged to see the emergence of a sizable and durable long-term COVID vaccine market"
        ],
        "marketData": {
          "priceOnEarningsDate": 41.58000183105469,
          "priceAfter7Days": 47.529998779296875,
          "priceChangePercent": 14.30975634012199,
          "managementToneScore": 25,
          "earningsBeatScore": 50,
          "priceActionScore": 90,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 60,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q4 2024",
      "quarterInfo": {
        "calendarQuarter": 4,
        "calendarYear": 2024,
        "fiscalQuarter": 4,
        "fiscalYear": 2024,
        "quarter": "Q4 2024",
        "reportDate": "2024-12-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0001682852-24-000060",
        "filingDate": "2024-11-07",
        "reportDate": "2024-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/1682852/000168285224000060/mrna-20240930.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "stable",
        "revenue": 1820,
        "netIncome": 13,
        "operatingCashFlow": -3829,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 474,
        "marketShareMention": null,
        "customerConcentration": null,
        "geographicBreakdown": {
          "United States": 66.7,
          "Europe": 15.4,
          "Rest of World": 17.9
        },
        "capexAmount": 529,
        "capexGrowth": null,
        "partnerships": [
          "Blackstone Life Sciences research funding",
          "Merck individualized neoantigen therapy collaboration"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "neutral",
        "summary": "Moderna delivered stable quarterly revenue of $1.82B, driven by COVID-19 vaccine sales and the recent launch of its RSV vaccine. The company maintained a cautious outlook while continuing to advance its diverse pipeline of mRNA therapeutics and vaccines.",
        "keyQuotes": [
          "We have a diverse and extensive development pipeline of 36 development candidates across our 45 development programs, of which 42 are in clinical studies currently.",
          "In May 2024, the U.S. Food and Drug Administration (FDA) granted approval for mRESVIAÂ®, our second approved mRNA product"
        ],
        "marketData": {
          "priceOnEarningsDate": 66.83000183105469,
          "priceAfter7Days": 58.720001220703125,
          "priceChangePercent": -12.135269172748986,
          "managementToneScore": 65,
          "earningsBeatScore": 50,
          "priceActionScore": 5,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 38,
          "compositeSentiment": "bearish"
        }
      },
      "quarter": "Q3 2024",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2024,
        "fiscalQuarter": 3,
        "fiscalYear": 2024,
        "quarter": "Q3 2024",
        "reportDate": "2024-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0001682852-24-000046",
        "filingDate": "2024-08-01",
        "reportDate": "2024-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/1682852/000168285224000046/mrna-20240630.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "stable",
        "revenue": 241,
        "netIncome": -1279,
        "operatingCashFlow": -2263,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 797,
        "marketShareMention": "Transitioned to seasonal commercial market for COVID-19 vaccine",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United_States": 67.2,
          "Europe": 0,
          "Rest_of_World": 9.1
        },
        "capexAmount": 378,
        "capexGrowth": null,
        "partnerships": [
          "Merck for individualized neoantigen therapy",
          "Mitsubishi Tanabe Pharma for co-promotion in Japan",
          "BARDA for pandemic influenza vaccine development"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "neutral",
        "summary": "Moderna is transitioning to a seasonal commercial market for its COVID-19 vaccine with reduced first-half sales. The company received FDA approval for its RSV vaccine and continues to advance its diversified pipeline across multiple therapeutic areas.",
        "keyQuotes": [
          "We anticipate that the demand for our COVID-19 vaccine will be higher in the fall and winter seasons across both hemispheres",
          "Our pipeline builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing",
          "We have a diverse and extensive development pipeline of 40 development candidates across our 47 development programs"
        ],
        "marketData": {
          "priceOnEarningsDate": 115.94999694824219,
          "priceAfter7Days": 116.44999694824219,
          "priceChangePercent": 0.4312203649502382,
          "managementToneScore": 65,
          "earningsBeatScore": 50,
          "priceActionScore": 55,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 53,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q2 2024",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2024,
        "fiscalQuarter": 2,
        "fiscalYear": 2024,
        "quarter": "Q2 2024",
        "reportDate": "2024-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0001682852-24-000027",
        "filingDate": "2024-05-02",
        "reportDate": "2024-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/1682852/000168285224000027/mrna-20240331.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "lowered",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "expanding",
        "revenue": 167,
        "netIncome": -1175,
        "operatingCashFlow": -989,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 580,
        "marketShareMention": "COVID-19 vaccine market transitioning to seasonal commercial pattern",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United_States": 60,
          "Europe": 0,
          "Rest_of_World": 40
        },
        "capexAmount": 196,
        "capexGrowth": null,
        "partnerships": [
          "Blackstone Life Sciences for influenza vaccine funding",
          "Merck for individualized neoantigen therapy",
          "Merck",
          "Blackstone Life Sciences",
          "Biomedical Advanced Research and Development Authority"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": true,
        "priorGuidanceHit": null,
        "managementTone": "defensive",
        "overallSentiment": "bearish",
        "summary": "Moderna experienced a significant decline in COVID-19 vaccine sales as the market transitions to a seasonal commercial pattern. The company is focusing on pipeline diversification and advancing multiple vaccine and therapeutic programs across different disease areas.",
        "keyQuotes": [
          "We anticipate that the demand for our COVID-19 vaccine will be higher in the fall and winter seasons across both hemispheres, as countries prepare for seasonal vaccination campaigns.",
          "Research and development continues to be our top capital allocation priority."
        ],
        "marketData": {
          "priceOnEarningsDate": 105.5999984741211,
          "priceAfter7Days": 105.08999633789062,
          "priceChangePercent": -0.48295657537859965,
          "managementToneScore": 5,
          "earningsBeatScore": 50,
          "priceActionScore": 45,
          "guidanceAccuracyScoreWeighted": 30,
          "compositeSentimentScore": 40,
          "compositeSentiment": "bearish"
        }
      },
      "quarter": "Q1 2024",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2024,
        "fiscalQuarter": 1,
        "fiscalYear": 2024,
        "quarter": "Q1 2024",
        "reportDate": "2024-03-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0001682852-24-000015",
        "filingDate": "2024-02-23",
        "reportDate": "2023-12-31",
        "form": "10-K",
        "url": "https://www.sec.gov/Archives/edgar/data/1682852/000168285224000015/mrna-20231231.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "lowered",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "stable",
        "revenue": 2771,
        "netIncome": null,
        "operatingCashFlow": null,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": null,
        "geographicBreakdown": null,
        "capexAmount": null,
        "capexGrowth": null,
        "partnerships": [
          "Merck - Individualized Neoantigen Therapies",
          "Chiesi Farmaceutici - Pulmonary Arterial Hypertension",
          "Carisma Therapeutics - CAR-M therapeutics",
          "CytomX Therapeutics - mRNA-based conditionally activated therapies",
          "Generation Bio - Non-viral genetic platform",
          "Immatics - Cancer therapies",
          "Life Edit Therapeutics - In vivo mRNA gene editing",
          "Metagenomi - Gene editing systems",
          "Vertex",
          "Merck",
          "AstraZeneca",
          "National Institute of Allergy and Infectious Diseases",
          "Takeda Pharmaceutical Company",
          "Ministry of Health Labor and Welfare of Japan",
          "UK Health Security Agency",
          "FFF Enterprises",
          "European Commission",
          "US Government",
          "Immatics",
          "Ori Ciro Genomics KK"
        ],
        "supplyChainStatus": "tight",
        "regulatoryHeadwinds": [
          "Ongoing FDA scrutiny of COVID-19 vaccine safety",
          "Potential classification of mRNA therapies as gene therapies",
          "Post-marketing safety study requirements"
        ],
        "aiInvestmentMentioned": true,
        "priorGuidanceHit": null,
        "managementTone": "cautious",
        "overallSentiment": "neutral",
        "summary": "Moderna is transitioning from pandemic emergency response to an endemic COVID-19 vaccine market, with significantly lower expected revenues in 2024. The company continues to invest in diversifying its pipeline across respiratory, oncology, and rare disease therapies while managing manufacturing infrastructure and regulatory challenges.",
        "keyQuotes": [
          "In 2023, the COVID-19 vaccine market transitioned to an endemic, seasonal commercial market",
          "We are advancing a broader seasonal respiratory vaccine franchise",
          "We believe that our ability to move with both scale and speed positions us well to pursue our goals related to future product launches"
        ],
        "marketData": {
          "priceOnEarningsDate": 112.5,
          "priceAfter7Days": 115.44000244140625,
          "priceChangePercent": 2.6133355034722223,
          "managementToneScore": 45,
          "earningsBeatScore": 50,
          "priceActionScore": 55,
          "guidanceAccuracyScoreWeighted": 30,
          "compositeSentimentScore": 47,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q4 2023",
      "quarterInfo": {
        "calendarQuarter": 4,
        "calendarYear": 2023,
        "fiscalQuarter": 4,
        "fiscalYear": 2023,
        "quarter": "Q4 2023",
        "reportDate": "2023-12-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0001682852-23-000042",
        "filingDate": "2023-11-03",
        "reportDate": "2023-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/1682852/000168285223000042/mrna-20230930.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "lowered",
        "bookingsGrowth": null,
        "pricingPower": "weak",
        "headcountTrend": "reducing",
        "revenue": 1757,
        "netIncome": -3630,
        "operatingCashFlow": -3740,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 1372,
        "marketShareMention": "Transitioning to endemic seasonal COVID-19 vaccine market",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United_States": 52,
          "Europe": 6,
          "Rest_of_World": 42
        },
        "capexAmount": 487,
        "capexGrowth": null,
        "partnerships": [
          "Immatics - strategic R&D collaboration in October 2023",
          "Generation Bio - strategic collaboration in March 2023",
          "Vertex",
          "Merck",
          "AstraZeneca",
          "Generation Bio Co",
          "Immatics",
          "The Bill and Melinda Gates Foundation",
          "Biomedical Advanced Research and Development Authority",
          "Defense Advanced Research Projects Agency",
          "Ori Ciro Genomics KK"
        ],
        "supplyChainStatus": "tight",
        "regulatoryHeadwinds": [
          "FDA guidance on COVID-19 vaccine composition",
          "Potential challenges in vaccine market transition"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": false,
        "managementTone": "defensive",
        "overallSentiment": "bearish",
        "summary": "Moderna is experiencing significant revenue decline as the COVID-19 vaccine market transitions to a seasonal model. The company is taking strategic steps to resize manufacturing, including inventory write-downs and reduced purchase commitments, while facing challenges in maintaining profitability.",
        "keyQuotes": [
          "A continued shift in product demand to the latest variant-targeted COVID-19 vaccine",
          "COVID-19 vaccine market continues to transition to an endemic seasonal market in 2023"
        ],
        "marketData": {
          "priceOnEarningsDate": 103.30999755859375,
          "priceAfter7Days": 101.83999633789062,
          "priceChangePercent": -1.4229031608188674,
          "managementToneScore": 5,
          "earningsBeatScore": 50,
          "priceActionScore": 45,
          "guidanceAccuracyScoreWeighted": 35,
          "compositeSentimentScore": 41,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q3 2023",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2023,
        "fiscalQuarter": 3,
        "fiscalYear": 2023,
        "quarter": "Q3 2023",
        "reportDate": "2023-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0001682852-23-000027",
        "filingDate": "2023-08-03",
        "reportDate": "2023-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/1682852/000168285223000027/mrna-20230630.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "lowered",
        "bookingsGrowth": null,
        "pricingPower": "weak",
        "headcountTrend": "stable",
        "revenue": 344,
        "netIncome": -1380,
        "operatingCashFlow": -2140,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 1732,
        "marketShareMention": "COVID-19 vaccine market shifting to endemic seasonal market",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United States": 0.6,
          "Europe": 17.4,
          "RestOfWorld": 67.1
        },
        "capexAmount": 347,
        "capexGrowth": null,
        "partnerships": [
          "Merck - individualized neoantigen therapy",
          "Generation Bio - nucleic acid therapeutics",
          "DARPA - mobile manufacturing prototype",
          "BARDA - COVID-19 vaccine development"
        ],
        "supplyChainStatus": "easing",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": false,
        "managementTone": "defensive",
        "overallSentiment": "bearish",
        "summary": "Moderna experienced a significant decline in COVID-19 vaccine sales as the market shifts to an endemic seasonal model. The company is diversifying its pipeline with multiple clinical-stage programs in vaccines and therapeutics, focusing on emerging areas like personalized cancer treatments and new infectious disease targets.",
        "keyQuotes": [
          "We have a diverse and extensive development pipeline of 45 development candidates across our 47 development programs, of which 39 are in clinical studies currently.",
          "These charges in 2023 were primarily driven by a continued shift in product demand to the latest variant-targeted COVID-19 vaccines and a decline in customer demand as the COVID-19 vaccine market continues to shift to an endemic seasonal market in 2023."
        ],
        "marketData": {
          "priceOnEarningsDate": 121.5,
          "priceAfter7Days": 118.87000274658203,
          "priceChangePercent": -2.1646067929366,
          "managementToneScore": 5,
          "earningsBeatScore": 50,
          "priceActionScore": 45,
          "guidanceAccuracyScoreWeighted": 35,
          "compositeSentimentScore": 41,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q2 2023",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2023,
        "fiscalQuarter": 2,
        "fiscalYear": 2023,
        "quarter": "Q2 2023",
        "reportDate": "2023-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0001682852-23-000021",
        "filingDate": "2023-05-04",
        "reportDate": "2023-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/1682852/000168285223000021/mrna-20230331.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "lowered",
        "bookingsGrowth": null,
        "pricingPower": "weak",
        "headcountTrend": "stable",
        "revenue": 1828,
        "netIncome": 79,
        "operatingCashFlow": -1225,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 1816,
        "marketShareMention": "Continuing to meet evolving endemic COVID-19 market needs",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United_States": 1,
          "Europe": 576,
          "Rest_of_World": 1251
        },
        "capexAmount": 113,
        "capexGrowth": null,
        "partnerships": [
          "Life Edit Therapeutics - gene editing therapies",
          "Generation Bio - nucleic acid therapeutics",
          "Government of Kenya - mRNA manufacturing facility",
          "Merck",
          "Vertex",
          "Generation Bio",
          "OriCiro Genomics",
          "Bill and Melinda Gates Foundation",
          "Defense Advanced Research Projects Agency",
          "Biomedical Advanced Research and Development Authority"
        ],
        "supplyChainStatus": "tight",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "cautious",
        "overallSentiment": "bearish",
        "summary": "Moderna's Q1 2023 results show a significant decline in COVID-19 vaccine sales compared to last year, with reduced revenues and lower net income. The company is diversifying its pipeline across multiple therapeutic areas while managing a challenging market transition.",
        "keyQuotes": [
          "We expect to continue to meet the evolving needs of the endemic COVID-19 market",
          "Our mRNA platform can produce variant-matched vaccines on an accelerated time horizon"
        ],
        "marketData": {}
      },
      "quarter": "Q1 2023",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2023,
        "fiscalQuarter": 1,
        "fiscalYear": 2023,
        "quarter": "Q1 2023",
        "reportDate": "2023-03-31"
      },
      "analyzedSuccessfully": true
    }
  ],
  "totalFetched": 12,
  "successfulAnalyses": 11,
  "lastUpdated": "2025-11-26T05:47:51.498Z"
}